Dolutegravir, film-coated tablet, 10mg, 25mg, 50mg, product-specific bioequivalence guidance

  • Email
  • Help
Current effective version

Adopted guideline

Reference numberEMA/CHMP/356874/2017
Published01/02/2018
Effective from01/08/2018
KeywordsBioequivalence, generics, dolutegravir
DescriptionThis document provides product-specific guidance on the demonstration of the bioequivalence of olutegravir.
Abbreviations
  • BCS Classification: Biopharmaceutics Classification System
  • AUC0-t: area under the plasma concentration curve from administration to last observed concentration at time t
  • Cmax: maximum plasma concentration


Document history

First version

Current version

Adopted guideline

 

Draft guideline

In operation: 01/08/2018-present

 

Published: 28/07/2017

Related content


How helpful is this page?

Average rating:

 Based on 20 ratings

Add your rating:

See all ratings
4 ratings
4 ratings
4 ratings
4 ratings
4 ratings
    

Tell us more